CN113699046A - 含有aif1细胞因子抗体的小球藻及其制备方法和应用 - Google Patents
含有aif1细胞因子抗体的小球藻及其制备方法和应用 Download PDFInfo
- Publication number
- CN113699046A CN113699046A CN202110911255.3A CN202110911255A CN113699046A CN 113699046 A CN113699046 A CN 113699046A CN 202110911255 A CN202110911255 A CN 202110911255A CN 113699046 A CN113699046 A CN 113699046A
- Authority
- CN
- China
- Prior art keywords
- aif1
- chlorella
- cytokine antibody
- antibody
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 title claims abstract description 86
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 title claims abstract description 86
- 241000195649 Chlorella <Chlorellales> Species 0.000 title claims abstract description 67
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 65
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 235000018102 proteins Nutrition 0.000 claims abstract description 31
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 241001522252 Crassostrea rivularis Species 0.000 claims abstract description 11
- 241000237502 Ostreidae Species 0.000 claims abstract description 9
- 235000020636 oyster Nutrition 0.000 claims abstract description 9
- 235000004252 protein component Nutrition 0.000 claims abstract description 5
- 235000019624 protein content Nutrition 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000007850 fluorescent dye Substances 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 238000001215 fluorescent labelling Methods 0.000 claims description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 7
- VQTBINYMFPKLQD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(3-hydroxy-6-oxoxanthen-9-yl)benzoate Chemical compound C=12C=CC(=O)C=C2OC2=CC(O)=CC=C2C=1C1=CC=CC=C1C(=O)ON1C(=O)CCC1=O VQTBINYMFPKLQD-UHFFFAOYSA-N 0.000 claims description 6
- 101150053137 AIF1 gene Proteins 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 238000005070 sampling Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 238000002474 experimental method Methods 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 4
- 230000003698 anagen phase Effects 0.000 claims description 4
- 238000011091 antibody purification Methods 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 238000001976 enzyme digestion Methods 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 238000011587 new zealand white rabbit Methods 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000005286 illumination Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 238000010839 reverse transcription Methods 0.000 claims description 3
- 230000031700 light absorption Effects 0.000 claims description 2
- 241000143060 Americamysis bahia Species 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 11
- 239000003550 marker Substances 0.000 abstract description 4
- 238000003125 immunofluorescent labeling Methods 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 13
- 239000012528 membrane Substances 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000002033 PVDF binder Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000012148 binding buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000009364 mariculture Methods 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 240000009108 Chlorella vulgaris Species 0.000 description 4
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000606651 Rickettsiales Species 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- -1 China) Chemical compound 0.000 description 1
- 241000548230 Crassostrea angulata Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 101001044093 Homo sapiens Lipopolysaccharide-induced tumor necrosis factor-alpha factor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100021607 Lipopolysaccharide-induced tumor necrosis factor-alpha factor Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Physics & Mathematics (AREA)
- Birds (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于生物技术领域,涉及含有AIF1细胞因子抗体的小球藻及其制备方法和应用。本发明采用纯化出来的近江牡蛎AIF1细胞因子抗体蛋白制品标记FITC荧光标记,以pVEC穿膜肽为载体将AIF1细胞因子抗体蛋白分子导入小球藻,在室温黑暗条件下,进行AIF1细胞因子抗体孵育小球藻,从而获得含有AIF1细胞因子抗体分子物质成分的小球藻种类。用抗体分子免疫荧光标记生物学技术、激光共聚焦显微镜检测、验证小球藻体内含有牡蛎AIF1细胞因子抗体蛋白质成分及其含量。
Description
技术领域
本发明属于生物技术领域,涉及含有AIF1细胞因子抗体的小球藻及其制备方法和应用。
背景技术
“蓝色海洋产业”是当今人类解决人口过剩与陆地资源短缺这一矛盾的重要源泉,但随着海水养殖产业(包括贝类、虾类和鱼类养殖产业)的发展,海水养殖病害的暴发和流行给海水养殖产业的发展以极大的打击,成为这一产业发展的“瓶颈”制约因素。因此,人们迫切地需要解决下列两个重大的问题:即病害的“防”与“治(或曰控制)”,而解决“防”与“控制”的关键就是:一要解决流行病的快速检测问题,做到疾病暴发前的早诊断;二要解决养殖动物自身抵抗力的问题即免除病原感染,降低养殖动物群体的大规模死亡。国际上应用分子生物学技术(包括分子免疫学)防治海水养殖动物病害是当今国内外海水养殖病害研究的主攻发展方向,这些技术包括各种分子及免疫快速检测技术、各种分子疫苗技术、各种细胞或免疫因子、基因工程技术等。但是,目前国内外尚未有采用高效价细胞因子抗体技术来获得贝类、虾类和鱼类养殖产业生产中抗病的免疫饵料及抗菌微生态免疫制剂制备的技术和产品。
我们前期对AIF1对革兰氏阴性菌成份LPS和类立克次氏体(RLO)抗感染的研究显示:牡蛎AIF1(Ca-AIF1)多克隆兔抗血清能显著抑制类立克次氏体(RLO)和LPS刺激引起的炎症相关因子LITAF的表达(LPS+anti-Ca-AIF1,1.5-12小时分别降低70.95%,84.18%,39.49%和87.53%;RLO+anti-Ca-AIF1,1.5-12小时分别降低88.57%,84.80%,59.36%和59.16%),说明Ca-AIF1多克隆抗血清具有有效抑制RLO感染和革兰氏阴性菌引起的炎症反应的作用。再比如,Ca-AIF1抗血清能够显著抑制RLO感染和革兰氏阴性菌引起的细胞凋亡和细胞坏死,显著增加细胞存活率,RLO+anti-Ca-AIF1实验组和LPS+anti-Ca-AIF1实验组活细胞数分别增加了51%和49%;而晚期凋亡细胞率分别减少了约50%和18%。
发明内容
针对上述现有技术中存在的缺乏,本发明提供了含有AIF1细胞因子抗体驯化培养小球藻及其制备方法。
一种含有AIF1细胞因子抗体的小球藻。
含有AIF1细胞因子抗体的小球藻的制备方法,采用纯化出来的近江牡蛎AIF1细胞因子抗体蛋白制品标记FITC荧光标记,以pVEC穿膜肽为载体将AIF1细胞因子抗体蛋白分子导入小球藻,在室温黑暗条件下,进行AIF1细胞因子抗体孵育小球藻,从而获得含有AIF1细胞因子抗体的小球藻。
其中,AIF1细胞因子抗体的制备包括如下步骤:
1)以近江牡蛎血淋巴细胞总RNA为模板,反转录成一链cDNA,克隆获得AIF1基因的编码框核苷酸序列;
2)将AIF1基因编码框的序列片段克隆到pMD19-T载体中,再经限制性内切酶酶切,与经同样酶切的pET-32(a)原核表达载体连接,获得重组表达质粒pET-32(a)-AIF1;
3)将阳性重组质粒PET-32(a)-AIF1转化到表达宿主菌E.coli Rossetta(DE3),异丙基硫代半乳糖苷(IPTG)诱导表达,SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)进行检测;
4)将阳性表达菌液扩大培养,利用蛋白质纯化试剂盒分离纯化重组蛋白质;
5)将纯化的AIF1蛋白多点注射新西兰大白兔,制备纯化多克隆抗体。
AIF1细胞因子抗体蛋白分子导入小球藻包括如下步骤:
1.AIF1细胞因子抗体纯化及绿色荧光标记
1.1AIF1细胞因子多克隆抗体纯化
采用Protein A Sepharose亲和层析柱(索莱宝,中国)按照说明书纯化获得抗血清的总IgG。具体方法如下:使用Binding buffer(0.15M NaCl,20mM Na2HPO4,pH 7.0)调节血清至pH 7.0,上样至层析柱,依次用约10倍柱体积的Binding buffer(pH 7.0)洗除杂质,最后用洗脱buffer(100mmol/L甘氨酸,pH3.0)解吸附并收集蛋白,收集的蛋白立即用1.0mol/L Tris-HCl(pH 8.0)中和,-20℃保存。
1.2纯化的AIF1细胞因子多克隆抗体荧光标记
使用NHS-Fluorescein(Pierce,美国)标记纯化的AIF1多克隆抗体,步骤如下:取1ml 浓度为7.88mg/ml的纯化AIF1多克隆抗体转移至1.5ml无菌离心管中,加入37μl浓度为10mg/ml的NHS-Fluorescein荧光溶液,4℃反应24h。反应完成后将反应产物装入透析袋(Viskase,美国)中置于1L PBS中透析(4度),去除未结合度荧光素,换3次透析液,透析完全(透析外液为透明无色溶液)后取出偶联产物。稀释5倍后,分别测定A280 和A493吸光度值检测标记蛋白浓度和荧光标记率。
2.小球藻培养及生长曲线绘制
实验所用小球藻由广西壮族自治区海洋研究所馈赠,采用f/2培养液(225mg/LNaNO3, 5mg/L KH2PO4,100mg/LNaHCO3,200μg/L维生素B12,200μg/L维生素B1,)进行传代培养,将无菌小球藻按照1:10比例接种到新鲜培养基中,培养条件:温度23℃,光照强度3000lx,光暗周期比为12h:12h。每隔24h无菌条件下取藻样于酶标仪上测定660 nm处吸光值,绘制小球藻生长曲线,每个时间点执行3个生物学重复。
3.AIF1细胞因子抗体导入小球藻
收集处于对数生长期的小球藻并离心(400×g,10min),使用无菌PBS 洗涤小球藻3次,使用细胞计数板显微镜下计数将浓度调整为106cell/mL,离心去掉上清液。将100μl终浓度为100μg/ml AIF1抗体与终浓度为20μM pVEC混合后加入藻沉淀中,使其浓度为106cell/mL。室温暗室中孵育,分别在孵育15min,30min时取样置于载玻片上, 50%甘油封片于共聚焦显微镜下观察拍照,每个实验设置3个生物学重复。
进一步的,采用激光共聚焦显微镜检测、验证小球藻体内含有牡蛎AIF1细胞因子抗体蛋白质成分及其含量。
另外,本发明还提供了含有AIF1细胞因子抗体的小球藻用于制备贝类及鱼虾病害抗感染防治的免疫抗病饵料应用。
所述应用为制备抗革兰氏阴性菌和类立克次氏体(RLO)感染的免疫饵料。
本发明还提供一种饵料,包含含有AIF1细胞因子抗体的小球藻。
本发明采用纯化出来的近江牡蛎AIF1细胞因子抗体蛋白制品标记FITC荧光标记,以pVEC 穿膜肽为载体将AIF1细胞因子抗体蛋白分子导入小球藻(备注:小球藻是培育牡蛎幼虫和鱼虾饵料的主要藻类),在室温黑暗条件下,进行AIF1细胞因子抗体孵育小球藻,从而获得含有AIF1细胞因子抗体分子物质成分的小球藻种类。用抗体分子免疫荧光标记生物学技术、激光共聚焦显微镜检测、验证小球藻体内含有牡蛎AIF1细胞因子抗体蛋白质成分及其含量。具有以下特点:
1.采用基因克隆技术,制备、纯化牡蛎促炎细胞因子AIF1蛋白质。
2.制备并且纯化抗抗革兰氏阴性菌和类立克次氏体(RLO)病的AIF1抗体蛋白分子(或制品)。
3.采用纯化出来的近江牡蛎AIF1细胞因子的抗体蛋白分子(或制品),进行AIF1细胞因子抗体分子导入小球藻的研究和小球藻驯化混合培养。
4.采用分子生物学技术(包括分子免疫学技术、蛋白质分离纯化技术、抗体分子免疫荧光标记生物学技术、激光共聚焦显微镜等)检测、验证小球藻体内含有近江牡蛎AIF1细胞因子抗体蛋白质成分及其含量。
本发明获得了AIF1细胞因子抗体蛋白分子导入小球藻的技术,含有牡蛎AIF1细胞因子抗体驯化培养的小球藻种类,获得了含有近江牡蛎AIF1细胞因子抗体驯化培养的小球藻用于制备抗革兰氏阴性菌和类立克次氏体(RLO)感染的免疫饵料,实现了病害递送给药方式上重大技术创新。
附图说明
图1 AIF1抗体滴度检测,其中1A:ELISA方法,1B:Western Blot。
图2共聚焦检测AIF1细胞因子导入小球藻,其中2A:FITC标记AIF抗体;2B:pVEC孵育 FITC抗体15min;2C:pVEC孵育FITC抗体30min。
图3穿膜肽pVEC介导AIF1抗体进入小球藻机制示意图。
具体实施方式
一、采用基因克隆技术,制备、纯化牡蛎促炎细胞因子AIF1蛋白质及其细胞因子抗体制备
1、以近江牡蛎血淋巴细胞总RNA为模板,反转录成一链cDNA,克隆获得AIF1基因的编码框核苷酸序列。
2、将AIF1基因编码框的序列片段克隆到pMD19-T载体(Takara公司,日本)中,再经限制性内切酶酶切,与经同样酶切的pET-32(a)原核表达载体(Novagen公司,美国)连接,获得重组表达质粒pET-32(a)-AIF1。
3、将阳性重组质粒PET-32(a)-AIF1转化到表达宿主菌E.coli Rossetta(DE3)(全式金,中国),异丙基硫代半乳糖苷(IPTG)(Sangon公司,加拿大)诱导表达,SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)进行检测。
4、将阳性表达菌液扩大培养,利用蛋白质纯化试剂盒分离纯化重组蛋白质。
5、将纯化的AIF1蛋白多点注射新西兰大白兔,制备纯化多克隆抗体。
具体的操作步骤如下:
1、近江牡蛎血淋巴细胞RNA提取和cDNA一链扩增
2、近江牡蛎AIF1编码框核苷酸全长序列的获得
根据NCBI数据库中AIF1(HM749971.1)基因序列设计特异性引物(AIF1F:CGCGGATCCATGTCGGTGGACTTCAAAG,AIF1R:CCGCTCGAGTGGCAGATCGGAGAGGGATTTC,下划线所示酶切位点分别为BamHI和XhoI),使用高保真酶(HS DNA Polymerase,TaKaRa,日本)克隆AIF1编码框核苷酸全长序列。反应条件为:94℃预变性5分钟,35个循环(94℃变性30s,55℃退火30s,72℃延伸30s),72℃延伸10min。PCR扩增连入PMD-19T载体,转化大肠杆菌DH5α(Takara公司,日本),挑取若干个克隆进行PCR鉴定及进一步的测序鉴定。
3、PET-32(a)-AIF1表达载体的构建
将步骤2中鉴定正确的阳性克隆子扩大培养提取质粒,使用BamHI、XhoI限制性内切酶(Takara公司,日本)双酶切,连接入经过同样双酶切的pET-32a载体的相应位点上,转化大肠杆菌DH5α(天根公司,中国)。PCR筛选阳性克隆,经测序鉴定获得编码框正确的表达载体pET-32(a)-AIF1。
4、重组蛋白质的表达
将步骤3中鉴定正确的阳性克隆子扩大培养提取重组质粒pET-32(a)-AIF1,转化至表达宿主菌E.coli Rossetta(DE3)感受态,使用菌落PCR筛选阳性克隆。将阳性菌按1:100 扩大培养至OD600为0.4-0.5时,加入终浓度为1mmol/L IPTG,继续培养4小时,离心收集宿主菌。细菌经超声波裂解后(300W,20min,超声2s,间隔3s)离心分离上清液和沉淀,进行SDS-PAGE电泳。
5、重组蛋白质的纯化和定量
将阳性表达菌扩大培养,按步骤4超声处理,利用Ni-NTA亲和层析柱(全式金,中国) 对表达产物进行分离纯化,并采用12%的SDS-PAGE进行电泳鉴定。
将纯化蛋白质使用Bradford蛋白质定量试剂盒(天根生化科技有限公司,中国)进行定量。
6、pET32a-AIF1多克隆兔抗血清制备
蛋白质定量后,取适量蛋白,挑选2只体重约2kg的健康新西兰大白兔(雄兔),进行多克隆抗体制备,用纯化所得的pET32a-AIF1为抗原加入等体积的佐剂充分乳化后免疫兔子,采用多点背部皮下注射,共免疫四次。
(1)免疫前,从耳静脉处收集3-5ml正常血清作为检测抗体时的阴性对照。
(2)用剪刀剪去兔子背部部分兔毛,酒精消毒后进行背部皮下多点注射。
(3)初次免疫:取约500μg抗原,加入等体积的完全弗氏佐剂充分乳化后注射,背部选取8-10个点,每个点注射约0.1ml;
(4)第二次免疫:间隔14d后进行,抗原量为500μg,加入等体积不完全弗氏佐剂充分乳化后注射,方法同上;
(5)第三、四次免疫:间隔14d后按同样方法进行,第四次免疫后,从耳静脉采血1ml分离血清,用双相琼脂扩散法进行免疫血清的抗体效价检测,效价应达到1:16以上才能放血;
(6)分离血清:第四次免疫后第7d,待抗体效价达到要求后,进行颈动脉采血并分离血清。分装后,-80℃保存。
7、AIF1细胞因子多克隆抗体效价测定
7.1ELISA(酶联免疫吸附)方法检测
用间接ELISA法测定免疫兔血清中AIF1特异性抗体滴度,具体步骤如下:
(1)抗原包被:用包被缓冲液将抗原稀释至1~10μg/ml,按100μl/孔加入酶标板中,覆膜,置于4℃过夜。
(2)洗涤:次日取出酶标板,倒掉孔中液体,置于纸上拍干;按300μl/孔加入TTBS,室温放置3min,倒掉拍干,共洗涤3次。
(3)封闭:往酶标板中加入封闭液200μl/孔,覆膜,37℃封闭1h。
(4)保存:倒掉封闭液,不必拍干,将封闭好的酶标板装入自封袋中置于-20℃保存待用。(注:酶标板上做好对于抗原标记;拿酶标板带手套。)
(5)一抗孵育:用封闭液稀释一抗,稀释梯度1:1000,1:3000,1:9000,1:27000,1:81000, 1:243000设置空白对照(封闭液),阴性对照(未免疫血液上清),梯度稀释过程中应充分混匀;稀释好后往酶标板中加入一抗稀释液100μl/孔,37℃孵育1h。
(6)孵育完后倒掉一抗,加入TTBS,300μl/孔,室温静置3min,共洗涤3次。
(7)二抗孵育:用封闭液稀释二抗(1:1000),洗涤完毕后,加入二抗稀释液100μl/孔,37℃孵育1h。
(8)孵育完毕后,用TTBS洗涤,300μl/孔,每次静置3min,洗完拍干,共洗涤4次。
(9)洗涤后将酶标板置于暗室中,加入150μl/孔TMB,待显呈梯度蓝色后加入50μl/孔2M的H2SO4,终止反应。(注:便于观察颜色变化可在酶标板下面垫一张白纸;加TMB的顺序应和加H2SO4,顺序一致。)
(10)将酶标板置于酶标仪中检测450nm吸光度。
(11)保存数据,对酶标板和数据打印纸拍照,做好记录。
7.2Western Blot(免疫印迹)方法检测
参照Sambrook等的方法进行(Sambrook J,Russell D W.Molecular Cloning:ALaboratory Manual,3rd ed.New York:Cold Spring Harbor Laboratory Press,2001),按一定比例稀释AIF1多克隆兔抗血清检测抗体效价,具体步骤如下:
(1)SDS-PAGE电泳:开始90V电泳,待跑到浓缩胶下面再调为150V直至电泳完毕。(注:点预染Marker)
(2)剪膜:剪跟胶大小一样的PVDF膜,并标明孔序和Marker位置,先用甲醇活化1-2min,再放入转膜Buffer中,并将两块滤纸、转移夹一并放入Buffer中。(注:Buffer盒子封闭避免甲醇挥发)
(3)转膜:电泳完毕,小心取下凝胶,切掉琼脂糖凝胶和浓缩胶后将胶置于Buffer中,打开转移夹(黑面朝下),先放一个湿润的滤纸,将凝胶放在滤纸上面,再将膜覆盖于凝胶之上,然后再盖上另一块滤纸,最后盖上转移夹置于Buffer中夹紧。安装好转移槽,在冰水浴中电泳,恒流180mA电泳2h。
(4)封闭:塑料盒中倒入一部分已配好的封闭液,电泳完毕取出PVDF膜,用甲醇活化1-2 min后吹干,将膜放入塑料盒中,再将塑料盒置于摇床上37℃封闭1h。
(5)孵育:用1.5ml离心管管取1ml封闭液,加入对应的一抗和二抗各(一般一抗二抗各1μl,具体根据抗体效价),充分混匀,再将膜放于塑料袋中,加入抗体稀释液后封口,置于摇床上37℃孵育1h。(注:PVDF膜尽量一直处于湿润状态)
(6)洗涤:孵育完成后,将膜放进塑料盒中加入适量TTBS溶液(淹没膜)置于摇床洗涤 3次,每次10min。
(7)凝胶成像系统曝光:配制显色液,每张膜需A液、B液各200μl(现配现用),将PVDF膜的水分吸干,然后将显色液均匀加在PVDF膜上,放入成像仪器中,设置曝光时间进行条带的显现。
二、AIF1细胞因子抗体蛋白分子导入小球藻
1.AIF1细胞因子抗体纯化及绿色荧光标记
1.1AIF1细胞因子多克隆抗体纯化
采用Protein A Sepharose亲和层析柱(索莱宝,中国)按照说明书纯化获得上述抗血清的总IgG。具体方法如下:使用Binding buffer(0.15M NaCl,20mM Na2HPO4,pH 7.0)调节血清至pH 7.0,上样至层析柱,依次用约10倍柱体积的Binding buffer(pH 7.0)洗除杂质,最后用洗脱buffer(100mmol/L甘氨酸,pH3.0)解吸附并收集蛋白,收集的蛋白立即用1.0mol/L Tris-HCl(pH 8.0)中和,-20℃保存。
1.2纯化的AIF1细胞因子多克隆抗体荧光标记
使用NHS-Fluorescein(Pierce,美国)标记纯化的AIF1多克隆抗体,步骤如下:取1ml 浓度为7.88mg/ml的纯化AIF1多克隆抗体转移至1.5ml无菌离心管中,加入37μl浓度为10mg/ml的NHS-Fluorescein荧光溶液,4℃反应24h。反应完成后将反应产物装入透析袋(Viskase,美国)中置于1L PBS中透析(4度),去除未结合度荧光素,换3次透析液,透析完全(透析外液为透明无色溶液)后取出偶联产物。稀释5倍后,分别测定A280 和A493吸光度值检测标记蛋白浓度和荧光标记率。
2.小球藻培养及生长曲线绘制
实验所用小球藻由广西壮族自治区海洋研究所馈赠,采用f/2培养液(225mg/LNaNO3, 5mg/L KH2PO4,100mg/LNaHCO3,200μg/L维生素B12,200μg/L维生素B1,)进行传代培养,将无菌小球藻按照1:10比例接种到新鲜培养基中,培养条件:温度23℃,光照强度3000lx,光暗周期比为12h:12h。每隔24h无菌条件下取藻样于酶标仪上测定660 nm处吸光值,绘制小球藻生长曲线,每个时间点执行3个生物学重复。
4.AIF1细胞因子抗体导入小球藻
收集处于对数生长期的小球藻并离心(400×g,10min),使用无菌PBS 洗涤小球藻3次,使用细胞计数板显微镜下计数将浓度调整为106cell/mL,离心去掉上清液。将100μl终浓度为100μg/ml AIF1抗体与终浓度为20μM pVEC混合后加入藻沉淀中,使其浓度为106cell/mL。室温暗室中孵育,分别在孵育15min,30min时取样置于载玻片上,50%甘油封片于共聚焦显微镜下观察拍照,每个实验设置3个生物学重复。
具体如下:
1、AIF1细胞因子多克隆抗体纯化
采用Protein A Sepharose亲和层析柱纯化AIF1多克隆抗体。具体方法如下:将Protein A Sepharose装柱,使用Binding buffer(0.15M NaCl,20mM Na2HPO4,pH 7.0)将制备的兔抗AIF1多克隆抗体血清调节pH至7.0,上样至Protein A Sepharose亲和层析柱,用10 倍柱体积的Binding buffer(pH 7.0)洗柱,最后用100mmol/L甘氨酸(pH3.0)洗脱蛋白并收集至1.5ml离心管中,收集的蛋白立即用1.0mol/L Tris-HCl(pH 8.0)中和,-20℃保存。
2、纯化的AIF1细胞因子抗体效价测定
通过ELISA和Western方法检测到制备的兔抗AIF1多克隆抗体效价超过1:243000,抗体滴度较高(图1)。
3、AIF1细胞因子多克隆抗体荧光标记
取1ml浓度为7.88mg/ml的纯化AIF1多克隆抗体转移至1.5ml无菌离心管中,加入37μl浓度为10mg/ml的NHS-Fluorescein荧光溶液,4℃反应24h。反应完成后将反应产物装入透析袋(Viskase,美国)中置于1L PBS中透析(4度),去除未结合度荧光素,换3次透析液,透析完全(透析外液为透明无色溶液)后取出偶联产物。稀释5倍后,测得 A280=1.066和A493=0.715,其中493nm为FITC的特异吸收峰,FITC的摩尔消光系数为 70000M-1cm-1,计算得到产物中FITC的摩尔浓度为5.11×10-5M;另外,FITC在280nm 处也有吸收,吸光度为493nm处的30%,因此AIF1抗体的吸光度为(1.066-0.715×0.3) ×5=4.26,抗体的摩尔消光系数为210000M-1cm-1,计算得到产物中抗体摩尔浓度为2.03 ×10-5M,抗体质量浓度为3.04mg/ml,FITC标记率为FITC:抗体=2.52:1。
4、荧光标记AIF1细胞因子多克隆抗体导入小球藻
收集处于对数生长期的小球藻并离心(400g,10min),使用无菌PBS洗涤小球藻3次,使用细胞计数板将其浓度调整为106cell/ml。移取100μL藻液至1.5mL无菌离心管,室温400g离心10min,去除上清收集沉淀。取100μLPBS至1.5mL离心管中,加入FITC 标记AIF1抗体和pVEC细胞穿膜肽使其终浓度分别为100μg/mL和20μM。将此混合物加入到藻沉淀中使藻悬浮。室温暗室中孵育,分别在孵育15min、30min取样置于载玻片上,50%甘油封片于共聚焦显微镜下观察拍照。由图2可见,当荧光标记AIF1抗体与小球藻孵育15min 时,仅个别小球藻(自发红色荧光)中含有绿色荧光(FITC标记AIF1抗体)(Fig.2A)。孵育时间达到30min时,可见小球藻中大量绿色荧光呈现(Fig.2B)。表明,AIF1多克隆抗体已成功导入小球藻中。图3为穿膜肽pVEC介导AIF1抗体进入小球藻机制示意图。
最后,还需要注意的是,以上列举的仅是本发明的若干具体实施例框架。显然,本发明不限于以上实施例,本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
序列表
<110> 吴信忠
<120> 含有AIF1细胞因子抗体的小球藻及其制备方法和应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 28
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
cgcggatcca tgtcggtgga cttcaaag 28
<210> 2
<211> 31
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
ccgctcgagt ggcagatcgg agagggattt c 31
Claims (8)
1.一种含有AIF1细胞因子抗体的小球藻。
2.权利要求1所述含有AIF1细胞因子抗体的小球藻的制备方法,采用纯化出来的近江牡蛎AIF1细胞因子抗体蛋白制品标记FITC荧光标记,以pVEC穿膜肽为载体将AIF1细胞因子抗体蛋白分子导入小球藻,在室温黑暗条件下,进行AIF1细胞因子抗体孵育小球藻,从而获得含有AIF1细胞因子抗体的小球藻。
3.根据权利要求2所述制备方法,其特征在于:AIF1细胞因子抗体的制备包括如下步骤:
1)以近江牡蛎血淋巴细胞总RNA为模板,反转录成一链cDNA,克隆获得AIF1基因的编码框核苷酸序列;
2)将AIF1基因编码框的序列片段克隆到pMD19-T载体中,再经限制性内切酶酶切,与经同样酶切的pET-32(a)原核表达载体连接,获得重组表达质粒pET-32(a)-AIF1;
3)将阳性重组质粒PET-32(a)-AIF1转化到表达宿主菌E.coli Rossetta(DE3),异丙基硫代半乳糖苷(IPTG)诱导表达,SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)进行检测;
4)将阳性表达菌液扩大培养,利用蛋白质纯化试剂盒分离纯化重组蛋白质;
5)将纯化的AIF1蛋白多点注射新西兰大白兔,制备纯化多克隆抗体。
4.根据权利要求2所述制备方法,其特征在于:AIF1细胞因子抗体蛋白分子导入小球藻包括如下步骤:
1)AIF1细胞因子抗体纯化及绿色荧光标记
采用Protein A Sepharose亲和层析柱纯化获得抗血清的总IgG;使用NHS-Fluorescein(Pierce,美国)标记纯化的AIF1多克隆抗体;
2)小球藻培养及生长曲线绘制
小球藻采用f/2培养液进行传代培养,将无菌小球藻按照1:10比例接种到新鲜培养基中,培养条件:温度23℃,光照强度3000lx,光暗周期比为12h:12h。每隔24h无菌条件下取藻样于酶标仪上测定660nm处吸光值,绘制小球藻生长曲线,每个时间点执行3个生物学重复;
3)AIF1细胞因子抗体导入小球藻
收集处于对数生长期的小球藻并离心(400×g,10min),使用无菌PBS
洗涤小球藻3次,使用细胞计数板显微镜下计数将浓度调整为106cell/mL,离心去掉上清液;将100μl终浓度为100μg/ml AIF1抗体与终浓度为20μM pVEC混合后加入藻沉淀中,使其浓度为106cell/mL;室温暗室中孵育,分别在孵育15min,30min时取样置于载玻片上,50%甘油封片于共聚焦显微镜下观察拍照,每个实验设置3个生物学重复。
5.根据权利要求2-4任一所述制备方法,其特征在于:采用激光共聚焦显微镜检测、验证小球藻体内含有牡蛎AIF1细胞因子抗体蛋白质成分及其含量。
6.权利要求1所述含有AIF1细胞因子抗体的小球藻用于制备鱼虾病害抗感染防治的免疫抗病饵料的应用。
7.根据权利要求6所述应用,所述应用为制备抗革兰氏阴性菌和类立克次氏体(RLO)感染的免疫饵料。
8.一种饵料,其特征在于:含有权利要求1所述含有AIF1细胞因子抗体的小球藻。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110911255.3A CN113699046A (zh) | 2021-08-10 | 2021-08-10 | 含有aif1细胞因子抗体的小球藻及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110911255.3A CN113699046A (zh) | 2021-08-10 | 2021-08-10 | 含有aif1细胞因子抗体的小球藻及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113699046A true CN113699046A (zh) | 2021-11-26 |
Family
ID=78651977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110911255.3A Pending CN113699046A (zh) | 2021-08-10 | 2021-08-10 | 含有aif1细胞因子抗体的小球藻及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113699046A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1354792A (zh) * | 1999-05-28 | 2002-06-19 | 爱尔基因泰克株式会社 | 用转化的微藻生物合成外源蛋白质 |
| CN102649815A (zh) * | 2012-05-15 | 2012-08-29 | 浙江大学 | Aif1蛋白及抗体在制备近江牡蛎抗感染免疫制剂中的应用 |
| US20160090603A1 (en) * | 2014-09-30 | 2016-03-31 | Sandia Corporation | Delivery platforms for the domestication of algae and plants |
-
2021
- 2021-08-10 CN CN202110911255.3A patent/CN113699046A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1354792A (zh) * | 1999-05-28 | 2002-06-19 | 爱尔基因泰克株式会社 | 用转化的微藻生物合成外源蛋白质 |
| CN102649815A (zh) * | 2012-05-15 | 2012-08-29 | 浙江大学 | Aif1蛋白及抗体在制备近江牡蛎抗感染免疫制剂中的应用 |
| US20160090603A1 (en) * | 2014-09-30 | 2016-03-31 | Sandia Corporation | Delivery platforms for the domestication of algae and plants |
Non-Patent Citations (1)
| Title |
|---|
| SEONGSU KANG等: "A highly efficient cell penetrating peptide pVEC-mediated protein delivery system into microalgae", ALGAL RESEARCH, vol. 24, pages 2 - 2 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104007261B (zh) | 禽三种呼吸道疾病三联快速检测试剂盒及应用 | |
| CN101788563B (zh) | 梅花鹿γ-干扰素双抗体夹心ELISA检测方法及试剂盒与应用 | |
| CN108396030B (zh) | 凡纳滨对虾抗菌肽基因Lv-BigPEN及其重组蛋白和应用 | |
| CN102703483B (zh) | 罗非鱼重组口服蛋白tat-gh及制备方法和应用 | |
| Sung et al. | Characterisation of monoclonal antibodies to haemocyte subpopulations of tiger shrimp (Penaeus monodon): immunochemical differentiation of three major haemocyte types | |
| CN109212230B (zh) | 用于检测犬细小病毒结构蛋白vp2抗体的致敏聚苯乙烯纳米微球及其制备方法和应用 | |
| CN101280021B (zh) | 抗对虾白斑综合症病毒工程蛋白vp28-cd及制备和用途 | |
| CN101241137A (zh) | 一种猪囊虫病金标快速诊断试剂 | |
| CN101538578A (zh) | 三基因融合的重组牛结核特异性抗原蛋白及制备方法 | |
| CN114732895B (zh) | 孢壁蛋白在拌饲投喂虾防控虾肝肠胞虫感染中的应用 | |
| CN116840463A (zh) | 大口黑鲈蛙虹彩病毒抗体胶体金试纸条及其制备方法和应用 | |
| CN102234657B (zh) | 一种抗鸡球虫病的融合蛋白及其制备和应用 | |
| CN101424689B (zh) | 蓝舌病病毒检测试纸条 | |
| CN113699046A (zh) | 含有aif1细胞因子抗体的小球藻及其制备方法和应用 | |
| Zhang et al. | Analysis of agglutinants elicited by antiserum of channel catfish immunized with extracellular proteins of virulent Aeromonas hydrophila | |
| CN113717858A (zh) | 含aif1细胞因子抗体的金鞭藻及其制备方法和应用 | |
| CN116925198B (zh) | 一种微孢子虫极管蛋白EcPTP1的重组蛋白及其制备方法和应用 | |
| CN102012432B (zh) | 基于重组ul51蛋白的胶体金免疫层析试纸及其制备方法和应用 | |
| CN114702574B (zh) | 白斑症病毒单链可变区重组抗体及其制备方法和应用 | |
| CN102360008A (zh) | 基于鸭瘟病毒 gG截段重组蛋白的试剂盒及其运用 | |
| CN113583141B (zh) | 猪流行性腹泻病毒Nsp9蛋白、含该Nsp9蛋白的融合蛋白及其制备方法和应用 | |
| CN114835804B (zh) | 一种猫传染性腹膜炎卵黄抗体组合物及其制备方法和应用 | |
| CN105481973A (zh) | 一种用于制备渔用免疫佐剂的多肽及其用途 | |
| CN109371043A (zh) | 田鼠巴贝虫2d33、2d36抗原蛋白及其应用 | |
| CN104558173B (zh) | 一种检测传染性脾肾坏死病毒的抗体及其制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |